Denali Therapeutics has become the latest on a growing list of biotechs to experience an FDA review delay in recent months. The agency in July accepted an application for Denali's enzyme replacement ...
Denali Therapeutics Inc. announced positive long-term data from its Phase 1/2 study of tividenofusp alfa (DNL310) in patients with Hunter syndrome (MPS II), showing sustained reductions in key disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results